Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

PDMR Dealings & Shareholding Update

Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy immunotherapies, announces that the Company has been notified by ZQ Group of the following.

A re-organisation took place within ZQ Group which involved the transfer of the majority of the Company's shares previously held by SkyGem Acquisition Limited to SkyGem International Holdings Limited, both entities being within ZQ Group (the "Transfer"). The Transfer was undertaken to optimise ZQ's internal holding structure of AGY shares. The Transfer did not result in any change to the ultimate beneficial ownership of Allergy Therapeutics plc.

Separately, SkyGem International Holdings Limited placed an aggregate of 209,600,000 shares to four investors at an average price of 10 pence per share. The shares placed are in the paper form and are restricted from trading in the AIM market within the twelve months following the placement. The placement was designed to optimise the shareholder base ahead of the Company's earlier announced plan of a potential dual listing in Hong Kong.

Following these transactions, ZQ Capital and related entities hold the following shares in Allergy Therapeutics plc:

The aggregate holdings above represent 60.5% of the Company's issued share capital. 

As a result of these transactions, Zheqing (Simon) Shen, a person discharging managerial responsibilities ("PDMR") by virtue of his position as a director of the Company, has notified the Company of the following dealings.

For further information, please contact:

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Geoff Nash /Giles Balleny/ Seamus Fricker

Nigel Birks - Life Science Specialist Sales

+44 (0)20 7220 0500

ICR Healthcare

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

[email protected]

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapies that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. For more information, please see www.allergytherapeutics.com.

 Notification and public disclosure of transactions by Director/persons discharging managerial responsibilities ("PDMR") and persons closely associated with them ("PCA")